Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Protara Therapeutics, Inc. (TARA)

Protara reports Q2 2026 net loss of $21.7 million, up from $15.0 million a year earlier

Negative Impact 3 of 5 earnings Written later

Protara Therapeutics reported a second-quarter 2026 net loss of $21.7 million, or $0.36 per share, compared with a net loss of $15.0 million, or $0.35 per share, in the prior-year period. The filing reports no revenue line, and the higher loss reflects increased research and development spending, while the company says its cash position is expected to fund operations into 2028.

Key points

  • Net loss of $21.7 million ($0.36 per share) for the quarter ended June 30, 2026, versus $15.0 million ($0.35 per share) a year earlier.
  • Research and development expenses rose to $17.0 million from $10.8 million; general and administrative expenses rose to $6.4 million from $5.8 million.
  • Cash, cash equivalents and marketable debt securities totaled $161.9 million as of June 30, 2026, which the company expects to support operations into 2028.
  • Enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial is expected to complete in the fourth quarter of 2026, and the ADVANCED-3 trial is being redesigned as an exploratory trial.

The filing

CompanyProtara Therapeutics, Inc. (TARA)
Form8-K, current report
Filed with the SECAug 11, 2026, 8:05 AM ET
Accession number0001213900-26-087506

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.